Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Updates in transplantation at ASH 2020

Corey Cutler • 15 Jan 2021
ASH 2020
Ruxolitinib
REACH3

Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA, discusses the most recent developments and emerging novel therapies for graft versus host disease (GvHD) including updates from the REACH3 trial (NCT03112603) of ruxolitinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Corey Cutler

1:40
The ROCKstar study: belumosudil for chronic GvHD
Corey Cutler • 15 Jan 2021
1:26
RIC allogeneic HCT for high-risk MDS
Corey Cutler • 15 Jan 2021
The content of VJHemOnc is intended for healthcare professionals